Vical Reports Expanded Potential Application For Vaxfectin Adjuvant
Vical has announced that systematic in vivo testing of its Vaxfectin adjuvant shows that it increased antibody and T-cell responses primarily by stimulating the immune system rather than
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.